NEWS

WIRES

OTHER

USAISR Researcher Dr. Andriy Batchinsky Identifies Vicor's PD2i(R) Nonlinear Algorithm as Most Promising Diagnostic for In-Field Trauma Triage in Presentation at the American Heart Association's Resuscitation Science Symposium 2009

David H. Fater, CEO of Vicor Technologies, Inc. (OTCBB: VCRT), today announced that Andriy Batchinsky, MD, a researcher with the U.S. Army Institute of Surgical Research (USAISR), identified Vicor's proprietary PD2i® nonlinear algorithm and software as the most promising diagnostic for in-field trauma triage during a presentation before several hundred attendees at the American Heart Association's Resuscitation Science Symposium 2009 on November 14, 2009 in Orlando, Florida. Vicor Technologies is a biotechnology company focused on the commercialization of innovative, non-invasive medical devices and diagnostics using its patented, proprietary PD2i® nonlinear algorithm and software to stratify patients at risk of sudden cardiac death and trauma victims in need of lifesaving intervention.

Dr. Batchinsky's presentation -- "Does Heart-Rate Complexity Analysis Work in the Real World? Changes in the Point Correlation Dimension of Heart Rate During Prehospital Lifesaving Interventions" -- provided a review of trauma triage diagnostics, including Vicor's PD2i® nonlinear algorithm and software, currently being evaluated by the USAISR. The American Heart Association's Resuscitation Science Symposium (ReSS) is an international forum for fundamental, translational, clinical, and population scientists and care providers to discuss recent advances related to treating cardiopulmonary arrest and life-threatening traumatic injury.

According to Dr. Batchinsky, current methods have proven inadequate in improving trauma triage on the battlefield; newer methods employing enhanced mathematical analysis of heart rate complexity (HRC) from EKG data are more promising in pristine, clinical settings, but have not proven reliable in real-world situations with only small amounts of "noisy" or "raw" data, and that the only diagnostic to provide consistently accurate results is Vicor's PD2i® nonlinear algorithm and software, which requires just one to two minutes of EKG data, and is not derailed in delivering actionable results by "noisy" or "raw" data.

"The data presented by Dr. Batchinsky clearly identifies Vicor's PD2i® nonlinear algorithm and software, from amongst other 'vital sign' diagnostics using EKG data to evaluate HRC, as a critical new trauma triage tool with the ability to consistently, accurately identify those requiring lifesaving intervention," stated Edward F. Lundy, MD, PhD. "Importantly, the PD2i® nonlinear algorithm is able to accomplish this lifesaving accuracy in real world situations where time is of the essence and the collection of 'clean' data is never guaranteed. As such, Vicor's PD2i® nonlinear algorithm is a new vital sign with the ability to actually save lives in both combat and civilian settings," Dr. Lundy concluded. Dr. Lundy is Chief of Cardiothoracic Surgery at the Active International Cardiovascular Institute at Good Samaritan Hospital in Suffern, New York and a member of Vicor's Scientific Advisory Board.

"We're extremely pleased and honored to have Dr. Batchinsky share the USAISR's validation of the efficacy of our PD2i® nonlinear algorithm at this well-attended, prestigious symposium," stated Mr. Fater. "Dr. Batchinsky has been actively involved in all of the clinical trials of the PD2i VS(TM) (Vicor's Vital Sign application of the PD2i® nonlinear algorithm) conducted under our collaborative agreement with the USAISR," stated Mr. Fater. "As such, he has directly witnessed the efficacy of the PD2i® nonlinear algorithm to consistently and accurately determine severity of injury and the probability of survival in critically injured soldiers and civilians utilizing both 'raw' and 'noisy' EKG data, which is consistent with the EKG data that will be collected from trauma victims in actual battlefield and emergency situations," Mr. Fater concluded.

Additional studies by the USAISR of automated trauma triage using the PD2i VS(TM) are planned.

About Vicor Technologies, Inc.

Vicor Technologies is a development-stage biotechnology company creating innovative non-invasive diagnostics employing its patented, proprietary point correlation dimension algorithm (PD2i®). The PD2i® nonlinear algorithm is a deterministic, nonlinear measure of electrophysiological potentials to predict future pathological events with a high degree of accuracy in target populations.

Vicor currently has three products employing the PD2i® nonlinear algorithm. The PD2i Analyzer(TM), which has FDA 510(k) marketing clearance, measures heart rate variability and Vicor will be commencing a clinical trial to determine its efficacy to detect the presence of diabetic autonomic neuropathy (DAN). The PD2i VS(TM) (Vital Sign), in clinical trials under a collaborative effort with the U.S. Army Institute for Surgical Research (http://www.usaisr.amedd.army.mil/), risk stratifies combat and civilian trauma victims. The PD2i CA(TM) (Cardiac Analyzer), in multiple clinical trials, identifies patients at risk of sudden cardiac death.

Vicor anticipates additional applications employing the PD2i® nonlinear algorithm to enable early detection and risk stratification for a variety of other disorders and diseases. Additional information is available at www.vicortech.com.

The appearance of name-brand institutions or products in this media release does not constitute endorsement by the U.S. Army Medical Research and Materiel Command, the Department of the Army, Department of Defense or the U.S. Government of the information, products or services contained therein.

Caution Regarding Forward-Looking Statements

Forward-looking statements in this press release are based on current plans and expectations that are subject to uncertainties and risks, which could cause our future results to differ materially. The following factors, among others, could cause our actual results to differ: our ability to obtain FDA approval of the PD2i VS(TM) (Vital Sign) for military and civilian applications and the PD2i CA(TM)(Cardiac Analyzer), our ability to continue to receive financing sufficient to continue operations and complete the critical clinical trials; our ability to continue as a going concern; our ability to successfully develop products based on our technologies; our ability to obtain and maintain adequate levels of third-party reimbursement for our products; the impact of competitive products and pricing; our ability to receive regulatory approval for our products; the ability of third-party contract research organizations to perform preclinical testing and clinical trials for our technologies; the ability of third-party manufacturers to manufacture our products; our ability to retain the services of our key personnel; our ability to market and sell our products successfully; our ability to protect our intellectual property; product liability; changes in federal income tax laws and regulations; general market conditions in the medical device and pharmaceutical industries; and other matters that are described in Vicor's Annual Report on Form 10-K for the fiscal year ended December 31, 2008 and subsequent filings with the Securities and Exchange Commission. Forward-looking statements in this press release speak only as of the date of the press release, and we assume no obligation to update forward-looking statements or the reasons why actual results could differ.

Release 09-20